How to Switch from Triptans to CGRP Medications

Triptans have been the gold standard for acute migraine treatment since sumatriptan's approval in 1992. They work by activating serotonin (5-HT1B/1D) receptors to constrict blood vessels and block pain pathways. While effective for many patients, triptans have significant limitations that drive the switch to CGRP-targeted therapy.

Reasons to consider CGRP medications:

• Triptans aren't working well enough — About 30–40% of patients don't respond adequately to triptans, and even responders may find them less effective over time
• Too many migraine days — If you're using triptans more than 8–10 days per month, you're at high risk for medication overuse headache (MOH). A CGRP preventive can reduce migraine frequency so you need less acute medication.
• Cardiovascular concerns — Triptans cause vasoconstriction and are contraindicated in patients with coronary artery disease, uncontrolled hypertension, history of stroke, or peripheral vascular disease. CGRP medications do not constrict blood vessels.
• Want prevention, not just rescue — Triptans only treat attacks after they start. CGRP preventives (mAbs and some gepants) reduce the number of attacks you get in the first place.
• Side effect burden — Triptans can cause chest tightness ("triptan sensation"), tingling, drowsiness, and fatigue. CGRP medications generally have a milder side effect profile.

Key distinction: Switching to CGRP therapy doesn't always mean stopping triptans. Many treatment plans use a CGRP mAb for prevention plus a triptan or gepant for acute rescue. Think of it as adding a preventive layer rather than replacing your entire approach — though if you have cardiovascular contraindications, gepants offer a triptan-free acute option.

CGRP (calcitonin gene-related peptide) is a molecule released during migraine attacks that causes blood vessel dilation and pain signaling. CGRP-targeted medications block this pathway through two different mechanisms:

1. Monoclonal Antibodies (mAbs) — Prevention Only:

• Aimovig (erenumab) — Targets the CGRP receptor. Monthly subcutaneous injection (70mg or 140mg). The only mAb that blocks the receptor rather than the CGRP molecule itself.
• Emgality (galcanezumab) — Targets the CGRP molecule. Monthly injection (120mg) after 240mg loading dose. Also FDA-approved for episodic cluster headache.
• Ajovy (fremanezumab) — Targets the CGRP molecule. Monthly injection (225mg) or quarterly injection (675mg — three injections at once). Only CGRP mAb with a quarterly option.

mAbs are large proteins with long half-lives (28–31 days), meaning they provide continuous prevention. They're injected subcutaneously (similar to insulin pens). They cannot be used for acute treatment.

2. Gepants (Small Molecule CGRP Receptor Antagonists) — Acute and/or Preventive:

• Nurtec ODT (rimegepant 75mg) — Oral dissolving tablet. FDA-approved for both acute treatment (take as needed) and preventive use (75mg every other day). The only medication in its class with dual approval.
• Ubrelvy (ubrogepant) — Oral tablet (50mg or 100mg). Acute treatment only. Take at migraine onset; can repeat after 2 hours if needed.
• Qulipta (atogepant) — Oral tablet (10mg, 30mg, or 60mg). Preventive use only. Taken daily. The only gepant approved exclusively for prevention.

Which type is right for you? If your primary need is reducing migraine frequency, a mAb (monthly injection) or Qulipta/Nurtec (daily/EOD pill) provides prevention. If you need a triptan alternative for acute treatment, Nurtec or Ubrelvy can replace triptans on a per-attack basis. Many patients use a combination — for example, Emgality for prevention plus Ubrelvy for breakthrough attacks.

Switching from triptans to CGRP medications is not an abrupt swap — it's typically a gradual transition with overlap:

Starting a CGRP preventive (mAb or gepant):

• Your neurologist or headache specialist prescribes the CGRP preventive
• You continue using your triptan for acute attacks during the transition. CGRP mAbs and triptans can be used together safely.
• CGRP mAbs take 4–12 weeks to reach full efficacy. The American Headache Society recommends a minimum 3-month trial before judging effectiveness.
• As migraine frequency decreases, you'll naturally need your triptan less often

Switching from triptan to gepant for acute use:

• If you're switching to Nurtec or Ubrelvy as your acute treatment, you can make the swap immediately — take the gepant instead of your triptan at the next migraine
• Gepants do not cause vasoconstriction, making them safe for patients with cardiovascular disease
• Gepants have a lower risk of medication overuse headache compared to triptans
• Onset of relief is similar: gepants typically provide pain freedom within 2 hours in 19–21% of patients (vs. 25–30% for sumatriptan)

Timeline for full transition:

• Weeks 1–4: Start CGRP preventive. Continue triptan for acute attacks. May notice gradual reduction in migraine frequency.
• Months 2–3: Migraine days should decrease. You may start needing your triptan less. Evaluate response at 3 months.
• Month 3+: If prevention is effective, some patients stop triptans entirely. Others keep them as backup for breakthrough attacks.

Insurance considerations: Most insurers require "step therapy" — you must have tried and failed 2–3 other preventives (typically a beta-blocker, topiramate, or antidepressant) before approving a CGRP medication. Your headache specialist can document your treatment history for prior authorization.

One of the biggest advantages of CGRP medications is their favorable side effect profile compared to triptans:

Triptan side effects you may leave behind:

• Chest tightness / pressure ("triptan sensation") — occurs in ~4–5% of patients
• Tingling / paresthesias
• Drowsiness and fatigue
• Dizziness
• Jaw/neck tightness
• Medication overuse headache risk (with frequent use)
• Cardiovascular vasoconstriction (contraindicated in CVD)

CGRP mAb side effects:

• Injection site reactions — Redness, pain, or swelling at injection site (most common, ~30–45%)
• Constipation — Particularly with Aimovig (erenumab), reported in ~3–4% of patients; can be severe in rare cases
• Antibody development — Small percentage develop anti-drug antibodies, potentially reducing efficacy over time
• Generally very well-tolerated; serious adverse events are rare

Gepant side effects:

• Nausea — 2–4% (ironically, given it treats nausea-associated migraines)
• Fatigue — reported in some patients with daily/EOD preventive use
• Liver enzyme elevation — Rare; periodic liver function monitoring may be recommended, especially with ubrogepant
• No vasoconstriction, no cardiovascular risk, no chest tightness

Bottom line: CGRP medications have a markedly better side effect profile than triptans for most patients. The main downsides are cost, injection site reactions (mAbs), and the need for ongoing use (preventive medications must be taken continuously to maintain benefit).